Sort
59,101 grants matching “hypertension”
Tulane BIRCWH
$435,408Tulane University Of Louisiana · K12 · FY2002 · HD
Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy
$435,382Tamie Chilcote · Activesite Pharmaceuticals, Inc. · R44 · FY2009 · EY
GRK4 and D3R regulation of NHE3 and NCC expression
$435,368Pedro A. Jose · University Of Virginia · P01 · FY2009 · HL
Administrative Core
$435,368Robin A Felder · University Of Virginia · P01 · FY2009 · HL
D1R and AT1R receptor interaction in human hypertension: clinical mechanisms
$435,368Robert Munson Carey · University Of Virginia · P01 · FY2009 · HL
Analytical Methods
$435,368John Joseph Gildea · University Of Virginia · P01 · FY2009 · HL
Spatiotemporal transregulation of D1-like angiotensin receptors in genetically...
$435,367Robin A Felder · University Of Virginia · P01 · FY2009 · HL
Astrocytic WNK-SPAK-NKCC1 Cascade in White Matter Astrogliosis and Injury
$435,363Mohammad Iqbal Hossain Bhuiyan · University Of Texas El Paso · R01 · FY2022 · NS
Role of Mitochondrial c-Src in Right Ventricular Dysfunction in Pulmonary Hypertension
$435,362Peng Zhang · Ocean State Research Institute, Inc. · R01 · FY2024 · HL
Personalized protein-protein interactomes and precision medicine in pulmonary arterial hypertension
$435,331Bradley Maron · Brigham And Women'S Hospital · R01 · FY2021 · HL
Systems biology, endothelial regulation of fibrosis, and pulmonary vascular disease
$435,314Bradley Maron · Brigham And Women'S Hospital · R01 · FY2019 · HL
The Role of Oxidative Signaling through Na/K-ATPase in Salt-Sensitive Hypertension
$435,300Jiang Liu · Marshall University · R15 · FY2016 · DK
Renal Cellular Metabolism and Hypertension
$435,247Mingyu Liang · Medical College Of Wisconsin · P01 · FY2021 · HL
Role of Gs-alpha in central regulation of energy and glucose metabolism
$435,159Lee Weinstein · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2016 · DK
EGF-ADAM17 axis in the pathophysiology of intracranial aneurysm
$435,140Tomoki Hashimoto · St. Joseph'S Hospital And Medical Center · R01 · FY2021 · NS
Caveolin-1 and vascular dysfunction
$435,055Luminita Pojoga · Brigham And Women'S Hospital · R01 · FY2010 · HL
DYSREGULATED ANGIOGENESIS IN SCLERODERMA-ASSOCIATED PAH
$435,049Fredrick M Wigley · Johns Hopkins University · P50 · FY2010 · HL
Comparative Effectiveness of Treat-To-Target Approach versus Routine Care in Management of Gout
$435,018Seoyoung Catherine Kim · Brigham And Women'S Hospital · R01 · FY2020 · AR
APOL1 variants: Understanding the basis of disparities in rates of kidney disease
$435,000Martin R. Pollak · Beth Israel Deaconess Medical Center · R01 · FY2012 · MD
National Estimates for Inpatient Care, Outcomes & Hospital Effect among Hispanics
$435,000Amresh D Hanchate · Boston Medical Center · R01 · FY2016 · MD
Molecular Mechanism of APOL1 Associated Kidney Disease
$435,000Martin R. Pollak · Beth Israel Deaconess Medical Center · R01 · FY2013 · MD
Role of Presenilin in Idiopathic Dilated Cardiomyopathy
$435,000Federica Del Monte · Beth Israel Deaconess Medical Center · R01 · FY2011 · HL
From QTL to Gene for HDL Cholesterol
$435,000Beverly J Paigen · Jackson Laboratory · R37 · FY2009 · HL
APOL1 variants: Understanding the basis of disparities in rates of kidney disease
$435,000Martin R. Pollak · Beth Israel Deaconess Medical Center · R01 · FY2016 · MD
National Estimates for Inpatient Care, Outcomes & Hospital Effect among Hispanics
$435,000Amresh D Hanchate · Boston Medical Center · R01 · FY2017 · MD